Vertex Pharmaceuticals Shares Owned by Institutions

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:3em;padding-top: 35px;;'>VRT</div>
VRTX -- USA Stock  

 Earnings Call  This Week

Vertex Pharmaceuticals shares-owned-by-institutions fundamental analysis lookup allows you to check this and other indicators for Vertex Pharmaceuticals Incorpor or any other equity instrument. You can also select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please continue to Equity Screeners to view more equity screening tools

Vertex Pharmaceuticals Shares Owned by Institutions Analysis

Shares Owned by Institutions show percentage of the outstanding shares of stock issued by a company that are currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
 2017 2018 2019 2020 (projected)
Receivables310.25 M414.87 M373.38 M402.86 M
Inventories111.83 M124.36 M111.92 M120.76 M
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKOSYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase III clinical trial VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain CTX001 that is in Phase III clinical trial for the treatment of beta-thalassemia and sickle cell diseases and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG Arbor Biotechnologies, Inc. Moderna Therapeutics, Inc. Genomics plc Merck KGaA Darmstadt, Germany X-Chem, Inc. Janssen Pharmaceuticals, Inc. Merck KGaA Kymera Therapeutics Ribometrix, Inc. and Molecular Templates, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Shares Held by Institutions 
Funds and Banks 
More About Shares Owned by Institutions | All Equity Analysis
Vertex Pharmaceuticals Shares Owned by Institutions  =
ValuationFundamentalsBuy or Sell

Vertex Pharmaceuticals Distress Driver Correlations

About Shares Owned by Institutions

Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Compare to competition
Accumulated Other Comprehensive Income
Based on latest financial disclosure 98% of Vertex Pharmaceuticals Incorpor are shares owned by institutions. This is 120.95% higher than that of the Healthcare sector, and 107.64% higher than that of Biotechnology industry, The Shares Owned by Institutions for all stocks is 151.54% lower than the firm.

Vertex Pharmaceuticals Shares Owned by Institutions Peer Comparison

  Shares Owned by Institutions 
  Vertex Pharmaceuticals Comparables 
Vertex Pharmaceuticals is rated below average in shares owned by institutions category among related companies.

Vertex Pharmaceuticals Institutional Holders

Current Institutional Investors

Security TypeSharesValue
New York State Teachers Retirement SystemCommon Shares366.2 K80.2 M
Strs OhioCommon Shares332.7 K72.8 M
Assenagon Asset Management SaCommon Shares269.4 K59 M
Manning Napier Group LlcCommon Shares219.2 K48 M
Welch Forbes LlcCommon Shares174.9 K38.3 M
Rhenman Partners Asset Management AbCommon Shares160 K35 M
State Of Michigan Retirement SystemCommon Shares146.2 K32 M

Vertex Pharmaceuticals current financial ratios